COVID-19

A 15-minute test for COVID-19 has just been approved

The portable test is about the size of a credit card. Image: Abbott Laboratories

Carl O'Donnell
Reporter , Reuters
Mrinalika Roy
Multimedia News Producer , Thomson Reuters
Share:
Our Impact
What's the World Economic Forum doing to accelerate action on COVID-19?
The Big Picture
Explore and monitor how COVID-19 is affecting economies, industries and global issues
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:

COVID-19

  • Abbott Laboratories has won approval for a COVID-19 portable antigen test that delivers results in 15 minutes and will sell for $5.
  • The portable coronavirus test is about the size of a credit card and requires no additional equipment to operate.

Abbott Laboratories said on Wednesday it won U.S. marketing authorization for a COVID-19 portable antigen test that can deliver results within 15 minutes and will sell for $5.

The portable test is about the size of a credit card, requires no additional equipment to operate, and can be conducted using a less invasive nasal swab than traditional lab tests, Abbott executives said on a call with reporters.

Abbott expects to ship tens of millions of tests in September, ramping to 50 million tests a month from the beginning of October.

The test, BinaxNOW COVID-19 Ag Card, could be used to check that people participating in larger gatherings, such as those returning to schools or workplaces, do not have COVID-19 and could help aid the reopening of the U.S., the executives said.

COVID-19 Global Health Healthy Futures SDG 03: Good Health and Well-Being Future of Health and Healthcare Healthcare Delivery Mental Health
Abbott expects to ship tens of millions of tests in September. Image: Abbott Laboratories

Abbott created a downloadable app that people who have taken the test could present before entering venues to show that they are COVID-19 free, they said.

Antigen tests are cheaper and faster than molecular diagnostic tests but somewhat more likely to fail to identify positive cases of the virus than lab-based diagnostic tests.

The U.S. Food and Drug Administration granted the approval under its emergency use authorization program. Becton Dickinson and Co and Quidel Corp already market antigen tests. (reut.rs/2QsSyOC)

The United States now has more cases of the coronavirus than any other country at more than 5 million, and hospitals and labs have struggled to meet the demand to test thousands of people.

Since March, the company has got U.S. authorizations for five other coronavirus tests, including one called the ID Now that can deliver results within minutes and is used at the White House.

Loading...
Loading...
Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Related topics:
COVID-19Global HealthHealth and HealthcareMental Health
Share:
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

Winding down COVAX – lessons learnt from delivering 2 billion COVID-19 vaccinations to lower-income countries

Charlotte Edmond

January 8, 2024

About Us

Events

Media

Partners & Members

  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2024 World Economic Forum